ContributorsPublishersAdvertisers

Biotech Co. Partners With Life Sciences Firms

investorideas.com
 11 days ago

Cover picture for the articleJanuary 12, 2022 (Investorideas.com Newswire) 2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report. Immuno-oncology cell therapy company, 2seventy bio inc. (TSVT:NASDAQ), entered into two recent agreements with the ultimate goal of developing a...

www.investorideas.com

Comments / 0

Comments / 0